Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05900882 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

StatusCompleted
PhasePhase 2
Started2022-07-15
View on ClinicalTrials.gov ↗

Amendment history

2026-09-01
Study Status, Study Design, Contacts/Locations v3
Trial completed
Final enrollment: 29 participants (planned 35)
Primary completion 2026-08-30, at least 365 days after the final estimate of 2025-08-30
Primary completion dateestimated 2025-08-30→confirmed 2026-08-30
Completion dateestimated 2025-08-30→confirmed 2026-08-30
Enrollment targetestimated 35→confirmed 29
Study sitesdetails revised at 6 of 6 sites
2025-08-13
Study Status, Contacts/Locations v2
Primary completion date2024-08-30→2025-08-30
Completion date2025-06-30→2025-08-30
Study sitescontacts updated at 5 of 6 sites
2023-08-09
Study Status, Eligibility v1
Eligibility criteria-1 characters
[...] mal (ULN)). Serum bilirubin≥1.5 × ULN. creatinine clearance ≥ <30 ml/min. History of active malignancy during the past 5 ye [...]
2023-06-11
Original filing
The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.
Trial Details
NCT Number NCT05900882
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions Multiple Myeloma
Enrollment 29 participants
Start Date 2022-07-15
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-02